Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

Transl Lung Cancer Res

Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center (a member of Beth Israel Lahey Health), Harvard Medical School, Boston, MA, USA.

Published: October 2019

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835108PMC
http://dx.doi.org/10.21037/tlcr.2019.05.12DOI Listing

Publication Analysis

Top Keywords

pd-l1 tumor
4
tumor proportion
4
proportion score
4
score key
4
key unlocking
4
unlocking keynote
4
keynote studies
4
studies pembrolizumab
4
pembrolizumab advanced
4
advanced lung
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!